ASD Defiance Autism Impact ETF
Quote as of Oct 09, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 26.45 | Day Range | 26.51 – 26.61 |
| 52-Week Range | 24.59 – 28.52 | Volume | 450 |
| Avg Volume | 506 | AUM | $1.3M (Oct 10, 2026) |
| Expense Ratio | 0.79% | Yield (TTM) | 0.03% |
| NAV | 26.20 | Premium/Discount | +1.58% indicative |
| Inception | Jun 01, 2026 | Holdings | 41 |
| Issuer | Defiance | Exchange | NASDAQ |
| Category | Developed Markets | Index Tracked | Not stated in source data |
| CUSIP | 268961331 | ISIN | US2689613311 |
| Management | Not stated in source data | ||
About this ETF
It operates as an exchange-traded investment fund.
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -2.04% | -2.87% | — | — | — | — | — | — | +8.10% |
| Total return | -2.02% | -2.85% | — | — | — | — | — | — | +8.17% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.79% | Annual cost of a $10,000 investment | $79.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 42 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Revvity Inc | PKI | 3.40% | 292 | $45.0K |
| 2 | BrightSpring Health Services Inc | BTSG | 2.93% | 608 | $38.8K |
| 3 | Pearson PLC | PSON.L | 2.89% | 2.25K | $38.2K |
| 4 | AbbVie Inc | ABBV | 2.88% | 138 | $38.2K |
| 5 | Medicover AB | MCOV-B.ST | 2.88% | 1.45K | $38.1K |
| 6 | Bright Horizons Family Solutions Inc | BFAM | 2.88% | 548 | $38.1K |
| 7 | Eli Lilly & Co | LLY | 2.85% | 32 | $37.7K |
| 8 | Teva Pharmaceutical Industries Ltd | TEVA.TA | 2.85% | 962 | $37.7K |
| 9 | Repligen Corp | RGEN | 2.84% | 216 | $37.6K |
| 10 | Graham Holdings Co | GHC | 2.84% | 32 | $37.5K |
| 11 | Stride Inc | LRN | 2.81% | 434 | $37.1K |
| 12 | Grand Canyon Education Inc | LOPE | 2.80% | 232 | $37.1K |
| 13 | Takeda Pharmaceutical Co Ltd | 4502.T | 2.79% | 1.00K | $36.9K |
| 14 | Otsuka Holdings Co Ltd | 4578.T | 2.78% | 500 | $36.8K |
| 15 | Novartis AG | NOVN.SW | 2.75% | 254 | $36.4K |
| 16 | Sumitomo Pharma Co Ltd | 4506.T | 2.73% | 3.60K | $36.2K |
| 17 | Roche Holding AG | ROP.SW | 2.73% | 84 | $36.2K |
| 18 | Acadia Healthcare Co Inc | ACHC | 2.73% | 1.23K | $36.1K |
| 19 | Pfizer Inc | PFE | 2.72% | 1.27K | $36.0K |
| 20 | Supernus Pharmaceuticals Inc | SUPN | 2.72% | 844 | $36.0K |
| 21 | H Lundbeck A/S | HLUN-B.CO | 2.67% | 5.13K | $35.3K |
| 22 | Johnson & Johnson | JNJ | 2.65% | 134 | $35.0K |
| 23 | Life Healthcare Group Holdings Ltd | LHC.JO | 2.65% | 47.53K | $35.0K |
| 24 | Definium Therapeutics Inc | DFTX | 2.60% | 934 | $34.5K |
| 25 | Neuren Pharmaceuticals Ltd | NEU.AX | 2.59% | 2.43K | $34.3K |
Click a ticker to see every ETF that owns it.
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.03% | Paid (last 12 months) | $0.0080 |
| Frequency | Quarterly | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Sep 23, 2026 | Last payment | $0.0020 (Sep 24, 2026) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Sep 23, 2026 | Sep 23, 2026 | Sep 24, 2026 | $0.0020 |
| Jun 24, 2026 | Jun 24, 2026 | Jun 25, 2026 | $0.0060 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
Liquidity
| Volume today | 450 | Average volume | 506 |
| AUM | $1.3M | Premium/Discount | +1.58% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$5.0K | -0.38% | $1.3M → $1.3M |
| 1 Month | -$38.1K | -2.79% | $1.4M → $1.3M |
| 1 Week | -$17.1K | -1.30% | $1.3M → $1.3M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for ASD
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.